Market Place
Sourcing Support
Cidara Announces Two Presentations On CD388 At IDWeek 2024
16 Oct 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Rule
04 Oct 2024 //
GLOBENEWSWIRE
Cidara Announces Two Presentations On CD388 At OPTIONS XII
25 Sep 2024 //
GLOBENEWSWIRE
Cidara Doses First Subjects In Phase 2b CD388 Flu Trial
23 Sep 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Strengthens Scientific Advisory Board
19 Sep 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Restructures To Focus On CD388 Development
12 Sep 2024 //
GLOBENEWSWIRE
Cidara To Present At H.C. Wainwright Investment Conference
05 Sep 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Taps Jim Beitel as Chief Business Officer
20 Aug 2024 //
CONTRACT PHARMA
Cidara Therapeutics Names Jim Beitel As Chief Business Officer
19 Aug 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule
03 Jul 2024 //
GLOBENEWSWIRE
Cidara To Present CD388 Preclinical Data At ASM Microbe 2024
30 May 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
15 May 2024 //
GLOBENEWSWIRE
Cidara Provides Update, Reports Q1 2024 Financial Results
15 May 2024 //
GLOBENEWSWIRE
Cidara Presents CD388 Phase 1/2a Data at ESCMID 2024
26 Apr 2024 //
GLOBENEWSWIRE
Cidara regains rights to flu med after Janssen makes good on promise to divest
25 Apr 2024 //
FIERCE BIOTECH
Cidara Divests Rezafungin to Mundipharma, Focuses on DFC Pipeline
24 Apr 2024 //
GLOBENEWSWIRE
Cidara Reacquires CD388 Rights, $240M Private Placement
24 Apr 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Reverse Stock Split
22 Apr 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
22 Apr 2024 //
GLOBENEWSWIRE
Cidara Provides Corporate Update, 2023 Financial Results
22 Apr 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Presents Promising Data at the AACR Annual Meeting 2024
05 Apr 2024 //
GLOBENEWSWIRE
Cidara to Present Data on Multiple Novel Drug-Fc Conjugate Candidates
06 Mar 2024 //
GLOBENEWSWIRE
Cidara Receives $11.14M Milestone Payment Following EU Approval of REZZAYO
12 Feb 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA
29 Jan 2024 //
GLOBENEWSWIRE
Cidara Therapeutics Announces European Approval of REZZAYO
22 Dec 2023 //
GLOBENEWSWIRE
Cidara Presents Promising Data on Novel Dual-Acting Drug-Fc Conjugates
07 Dec 2023 //
GLOBENEWSWIRE
Cidara Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin
06 Dec 2023 //
GLOBENEWSWIRE
Melinta & Cidara Announce Publication of Pooled Data from Phase 3 of REZZAYO
05 Dec 2023 //
BUSINESSWIRE
Cidara to Present Data on Novel Dual-Acting Drug-Fc Conjugates
30 Nov 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
20 Nov 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421
03 Nov 2023 //
GLOBENEWSWIRE
Cidara Provides Corporate Update & Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin
13 Oct 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Presents New Data on Novel Drug-Fc Conjugate CD388
11 Oct 2023 //
GLOBENEWSWIRE
Cidara Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Sep 2023 //
GLOBENEWSWIRE
Cidara to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
27 Sep 2023 //
GLOBENEWSWIRE
Cidara to Host R&D Day on its Cloudbreak Development Pipeline
07 Sep 2023 //
GLOBENEWSWIRE
Cidara Announces Janssen`s Election to Proceed Under its License Agreement
06 Sep 2023 //
GLOBENEWSWIRE
Cidara to Present at 25th Annual H.C. Wainwright Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Cidara Announces Appointment of Nicole Davarpanah as Senior Vice President
16 Aug 2023 //
GLOBENEWSWIRE
Details emerge on Cidara/J&J influenza partnership, with countdown on next steps
04 Aug 2023 //
ENDPTS
Cidara Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Provides Update on REZZAYOâ„¢ (rezafungin for injection)
31 Jul 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
20 Jul 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Added to Russell Microcap® Index
26 Jun 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388
22 Jun 2023 //
GLOBENEWSWIRE
Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC)
20 Jun 2023 //
GLOBENEWSWIRE
Cidara to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
13 Jun 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Cidara Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388
03 May 2023 //
GLOBENEWSWIRE
Cidara Receives $20M Milestone Payment Following FDA Approval of REZZAYOâ„¢
24 Apr 2023 //
GLOBENEWSWIRE
Cidara Therapeutics to Participate in Upcoming Investor Conferences
31 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Provides Corporate Update and 4Q & 2022 FYR
23 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO
22 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Closing of Public Offerings of Common Stock
07 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock
03 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock
02 Mar 2023 //
GLOBENEWSWIRE
Cidara Therapeutics Announces Promising Interim Ph2a Data Assessing CD388
01 Mar 2023 //
GLOBENEWSWIRE
